| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6190370 | Cancer Treatment Reviews | 2016 | 7 Pages |
Abstract
In this systematic review of the literature we explored the prognostic value of the PSA response to the neoadjuvant ADT phase and the rationale to adjust the use of ADT and EBRT in patients with intermediate- and high-risk prostate cancer based on the biochemical response to the neoadjuvant androgen ablation phase.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Thomas Zilli, Alan Dal Pra, Melpomeni Kountouri, Raymond Miralbell,